Sutro Biopharma Overview
DCF fair value estimate for Sutro Biopharma: $-0.82.
Get informed when a big investor buys or sells
+ Follow$-0.82
Overvalued by 103.8% based on the discounted cash flow analysis.
As of the most recent data, STRO shows a DCF fair value of $-0.82. Scroll down for historical charts and peer comparison views.
Sutro Biopharma's DCF reading of $-0.82 (103.8% overvalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether Sutro Biopharma's recent cash-flow history supports the assumptions.
Besides this discounted cash flow page, Stockcircle has Sutro Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $-0.82) with ownership activity and broader fundamentals.
Sutro Biopharma's DCF fair value is $-0.82; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
